FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3041099306> ?p ?o ?g. }

• W3041099306 abstract "Abstract Introduction The clinical relevance of low‐level viraemia (LLV) and virological outcomes among children living with HIV (CLHIV) remains controversial. This study aimed to determine the impact of LLV on virological failure (VF) among Asian CLHIV on first‐line combination antiretroviral therapy (cART). Methods CLHIV aged <18 years, who were on first‐line cART for ≥12 months, and had virological suppression (two consecutive plasma viral load [pVL] <50 copies/mL) were included. Those who started treatment with mono/dual antiretroviral therapy, had a history of treatment interruption >14 days, or received treatment and care at sites with a pVL lower limit of detection >50 copies/mL were excluded. LLV was defined as a pVL 50 to 1000 copies/mL, and VF as a single pVL >1000 copies/mL. Baseline was the time of the second pVL < 50 copies/mL. Cox proportional hazards models were performed to assess the association between LLV and VF. Results From January 2008 to September 2016, 508 CLHIV (55% female) were eligible for the study. At baseline, the median age was 9.6 (IQR: 7.0 to 12.3) years, cART duration was 1.4 (IQR: 1.3 to 1.8) years, 97% of CLHIV were on non‐nucleoside reverse transcriptase inhibitor‐based regimens, and the median CD4 was 25% (IQR: 20% to 30%). Over a median follow‐up time of 6.0 (IQR: 3.1 to 8.9) years from baseline, 86 CLHIV (17%) had ever experienced LLV, of whom 32 (37%) had multiple LLV episodes. Female sex, living in Malaysia (compared to Cambodia), having family members other than biological parents/grandparents as a primary caregiver, and baseline CD4 < 25% increased risk of LLV. Overall, 115 children (23%) developed VF, corresponding to a rate of 4.0 (95%CI: 3.4 to 4.9) per 100 person‐years of follow‐up (PYFU). VF was greater among children who had ever experienced LLV compared with those who maintained virological suppression throughout the study period (8.9 vs. 3.3 per 100 PYFU; p < 0.001). In multivariable analyses, ever experiencing LLV was associated with increased risk of subsequent VF (adjusted hazard ratio: 3.01; 95%CI: 1.97 to 4.60). Conclusions LLV increased the risk of subsequent VF among Asian CLHIV who had previously been suppressed on first‐line cART. Adherence interventions and additional targeted pVL monitoring may be warranted among children with LLV to facilitate early detection of VF." @default.
• W3041099306 created "2020-07-16" @default.
• W3041099306 creator A5000233611 @default.
• W3041099306 creator A5001627866 @default.
• W3041099306 creator A5004665455 @default.
• W3041099306 creator A5005175939 @default.
• W3041099306 creator A5005527678 @default.
• W3041099306 creator A5008178574 @default.
• W3041099306 creator A5011397666 @default.
• W3041099306 creator A5012259435 @default.
• W3041099306 creator A5013333974 @default.
• W3041099306 creator A5016527242 @default.
• W3041099306 creator A5017336801 @default.
• W3041099306 creator A5021243652 @default.
• W3041099306 creator A5026891474 @default.
• W3041099306 creator A5029606140 @default.
• W3041099306 creator A5032246043 @default.
• W3041099306 creator A5038323768 @default.
• W3041099306 creator A5040392063 @default.
• W3041099306 creator A5042121159 @default.
• W3041099306 creator A5042491405 @default.
• W3041099306 creator A5044952529 @default.
• W3041099306 creator A5047372123 @default.
• W3041099306 creator A5048763186 @default.
• W3041099306 creator A5051259565 @default.
• W3041099306 creator A5051559120 @default.
• W3041099306 creator A5052865554 @default.
• W3041099306 creator A5053316066 @default.
• W3041099306 creator A5056083261 @default.
• W3041099306 creator A5056294529 @default.
• W3041099306 creator A5056462251 @default.
• W3041099306 creator A5058310187 @default.
• W3041099306 creator A5058635535 @default.
• W3041099306 creator A5061419637 @default.
• W3041099306 creator A5063430422 @default.
• W3041099306 creator A5065640790 @default.
• W3041099306 creator A5071589370 @default.
• W3041099306 creator A5073318698 @default.
• W3041099306 creator A5073643745 @default.
• W3041099306 creator A5075265202 @default.
• W3041099306 creator A5077206842 @default.
• W3041099306 creator A5078158945 @default.
• W3041099306 creator A5080342844 @default.
• W3041099306 creator A5080713398 @default.
• W3041099306 creator A5081328251 @default.
• W3041099306 creator A5081943212 @default.
• W3041099306 creator A5082475777 @default.
• W3041099306 creator A5082902188 @default.
• W3041099306 creator A5082949830 @default.
• W3041099306 creator A5083059000 @default.
• W3041099306 creator A5085050174 @default.
• W3041099306 creator A5085502871 @default.
• W3041099306 creator A5087808566 @default.
• W3041099306 creator A5089309255 @default.
• W3041099306 creator A5017852278 @default.
• W3041099306 date "2020-07-01" @default.
• W3041099306 modified "2023-10-05" @default.
• W3041099306 title "Impact of low‐level viraemia on virological failure among Asian children with perinatally acquired HIV on first‐line combination antiretroviral treatment: a multicentre, retrospective cohort study" @default.
• W3041099306 cites W1517608807 @default.
• W3041099306 cites W1536823391 @default.
• W3041099306 cites W1589530118 @default.
• W3041099306 cites W1934867323 @default.
• W3041099306 cites W1969879877 @default.
• W3041099306 cites W1981023316 @default.
• W3041099306 cites W1986986909 @default.
• W3041099306 cites W2015068616 @default.
• W3041099306 cites W2031977727 @default.
• W3041099306 cites W2102925901 @default.
• W3041099306 cites W2106383584 @default.
• W3041099306 cites W2118240676 @default.
• W3041099306 cites W2120752160 @default.
• W3041099306 cites W2121743761 @default.
• W3041099306 cites W2123179942 @default.
• W3041099306 cites W2145283309 @default.
• W3041099306 cites W2149701672 @default.
• W3041099306 cites W2168628698 @default.
• W3041099306 cites W2323071838 @default.
• W3041099306 cites W2444219479 @default.
• W3041099306 cites W2619776367 @default.
• W3041099306 cites W2731882942 @default.
• W3041099306 cites W2769267084 @default.
• W3041099306 cites W2898678482 @default.
• W3041099306 cites W2900979445 @default.
• W3041099306 cites W2915360530 @default.
• W3041099306 cites W2961470236 @default.
• W3041099306 cites W3011059215 @default.
• W3041099306 doi "https://doi.org/10.1002/jia2.25550" @default.
• W3041099306 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7338042" @default.
• W3041099306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32628816" @default.
• W3041099306 hasPublicationYear "2020" @default.
• W3041099306 type Work @default.
• W3041099306 sameAs 3041099306 @default.
• W3041099306 citedByCount "4" @default.
• W3041099306 countsByYear W30410993062021 @default.
• W3041099306 countsByYear W30410993062023 @default.
• W3041099306 crossrefType "journal-article" @default.
• W3041099306 hasAuthorship W3041099306A5000233611 @default.
• W3041099306 hasAuthorship W3041099306A5001627866 @default.
• W3041099306 hasAuthorship W3041099306A5004665455 @default.
• W3041099306 hasAuthorship W3041099306A5005175939 @default.

• next